Bibliography
- CONTI M, JIN SL: The molecular biology of cyclicnucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. (1999) 63:1–38.
- GOLDENBERG MM: Safety and efficacy of sildenafilcitrate in the treatment of male erectile dysfunction. Ther. (1998) 20:1033–1048.
- HOFFMANN R, WILKINSON IR, MCCALLUM JF, ENGELS P, HOUSLAY MD: cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. Biochem. J. (1998) 333:139–149.
- HOUSLAY MD, SULLIVAN M, BOLGER GB: The multien-zyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol. (1998) 44:225–342.
- JIN SL, RICHARD FJ, KUO WP, D'ERCOLE AJ, CONTI M:Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc. Natl. Acad. ScL USA (1999) 96:11998–20003.
- KIKURA M, LEVY JH: New cardiac drugs. Int. AnesthesiolClin. (1995) 33:21–37.
- PASCAL Y, ANDRIANJARA CR, AUCLAIR E et al: Synthesisand structure-activity relationships of 4-oxo-1- phenyl-3,4,6,7-tetrahydro-[1,4] diazepino[6,7,1-hi] indoles: novel PDE4 inhibitors. Bioorg. Med. Chem. Lett. (2000) 10:35–38.
- SOUNESS JE, RAO S: Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodies-terases. Cell Signal (1997) 9:227–236.